FDA Clears Legend Biotech's LB2501 CAR — T Therapy for Clinical Trials
Legend Biotech received FDA clearance for its investigational new drug application for LB2501, a dual-targeting CD19/CD20 in vivo CAR-T therapy. The clearance supports a planned US Phase 1/2 trial in relapsed or refractory B-cell malignancies. Disclaimer: This news brief was created by Public Technologies (PUBT) using